Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Asylia Diagnostics
Beerse, Antwerp, Belgiumasyliadx.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Commercial
01
Overview
Conducting a retrospective clinical study to identify predictive biomarkers for hyperprogressive disease (HPD) in patients receiving immune checkpoint inhibitors. First clinically validated product is a molecular test for metastatic melanoma patients treated with PD-1 inhibitors to predict adverse events and therapy response.
- Therapeutic areas
- OncologyImmunologyRheumatology
- Modalities
- Molecular diagnosticsImmunotherapy companion diagnostics
- Industry
- Molecular Diagnostics
02
Partnerships
Pursuing partnerships with IVD and pharma companies
Beyond the preview
Go deeper on Asylia Diagnostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Asylia Diagnostics.